Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02726490 · ClinicalTrials.gov registry record · Early Phase 1
Glyburide vs Glucovance in the Treatment of GDM
A Early Phase 1 study, sponsored by Texas Tech University Health Sciences Center, El Paso.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT02726490: Clinical Trial Early Phase 1 study, sponsored by Texas Tech University Health Sciences Center, El Paso.
NCT02726490 is a Early Phase 1 study that was terminated before completion, run by Texas Tech University Health Sciences Center, El Paso. The registered enrollment target is 7 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02726490, a Early Phase 1 study, was terminated before completion, sponsored by Texas Tech University Health Sciences Center, El Paso.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
A randomized comparison of glyburide to glucovance (metformin -glyburide) in the management of diabetes in pregnancy.
Primary Outcome
failure rate of glyburide compared to glucovance in ability to achieve euglycemia
Interventions
- DRUG Glyburide
- DRUG Glucovance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-07 |
| Est. Completion | 2018-08-14 |
| Phase | Early Phase 1 |
Why NCT02726490 stopped before completion
NCT02726490 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Glyburide is the first listed.
NCT02726490 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02726490 about?
NCT02726490 is a clinical study titled "Glyburide vs Glucovance in the Treatment of GDM". A randomized comparison of glyburide to glucovance (metformin -glyburide) in the management of diabetes in pregnancy.
What is the current status of trial NCT02726490?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2016-07. Estimated completion is 2018-08-14.
What interventions are being tested in trial NCT02726490?
The interventions under investigation include: Glyburide (DRUG), Glucovance (DRUG).
Who is sponsoring clinical trial NCT02726490?
This trial is sponsored by Texas Tech University Health Sciences Center, El Paso, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02726490's enrollment target sits among peer trials
7 1825th of 2000 higher than 156 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia